Madhavi Pandiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Madhavi Pandiri has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Rojek
Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA
1 shared publicationAmandeep Kaur
Pathology (Molecular Pathology), Endeavor Health Northshore Hospital, Evanston, Illinois, USA
1 shared publicationAmi B. Patel
Pathology (Hematopathology), Internal Medicine (Hematology and Hematological Malignancies), The University of Utah School of Medicine, Salt Lake City, Utah, USA
1 shared publicationAnamarija Perry
Pathology (Division of Genomic Pathology & Hematopathology), University of Michigan, Ann Arbor, Michigan, USA
1 shared publicationAnisha Jacob
Pathology (Hematopathology & Cancer Cytogenetics), Medicine (Hematology/Oncology), The University of Chicago Medicine, Chicago, Illinois, USA
1 shared publicationAnna Stengel
MLL - Munich Leukemia Laboratory, Munich, Germany
1 shared publication
Latest Publications
- 30 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (18) , 2272
Rare composite of Rosai-Dorfman-Destombes disease and nodular lymphocyte-predominant B-cell (Hodgkin) lymphoma
- 30 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (18) , 2272
Rare composite of Rosai-Dorfman-Destombes disease and nodular lymphocyte-predominant B-cell (Hodgkin) lymphoma
- 26 June 2025
- Published by BMJ in Journal of Clinical Pathology
- Vol. 78 (9) , 629-635
Karyotypic clonal fraction predicts adverse outcome in TP53 -mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study
We investigated the prognostic impact of blast counts, TP53 allelic state determinants (number of hits, del(17p), variant allele frequency, complex karyotype),and a novel karyotypic clonal cell fraction (≤50% clonal cells vs >50% clonal cells (termed ‘CK50’)) in 495 individuals with TP53- mutated ( TP53 MUT ) myeloid neoplasms. Outcome examined was 24-month survival (OS24). The cohort (median age 71) included 29% (144/495) myelodysplastic syndromes (MDS)/MDS-acute myeloid leukaemia (AML) (1%–19% blasts) and 71% (351/495) AML (≥20% blasts), with 18% (81/460) having low CK50. Overall, 83% received front-line hypomethylating agents. Higher blast counts (TP53 allelic state determinants, only CK50 and complex karyotype remained relevant for predicting adverse outcomes.
- 26 June 2025
- Published by BMJ in Journal of Clinical Pathology
- Vol. 78 (9) , 629-635
Karyotypic clonal fraction predicts adverse outcome in TP53 -mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study
We investigated the prognostic impact of blast counts, TP53 allelic state determinants (number of hits, del(17p), variant allele frequency, complex karyotype),and a novel karyotypic clonal cell fraction (≤50% clonal cells vs >50% clonal cells (termed ‘CK50’)) in 495 individuals with TP53- mutated ( TP53 MUT ) myeloid neoplasms. Outcome examined was 24-month survival (OS24). The cohort (median age 71) included 29% (144/495) myelodysplastic syndromes (MDS)/MDS-acute myeloid leukaemia (AML) (1%–19% blasts) and 71% (351/495) AML (≥20% blasts), with 18% (81/460) having low CK50. Overall, 83% received front-line hypomethylating agents. Higher blast counts (TP53 allelic state determinants, only CK50 and complex karyotype remained relevant for predicting adverse outcomes.